Patents by Inventor Peter Kiener
Peter Kiener has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110059078Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.Type: ApplicationFiled: February 6, 2009Publication date: March 10, 2011Applicant: Medimmune, LLCInventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
-
Publication number: 20110008329Abstract: The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient.Type: ApplicationFiled: June 25, 2008Publication date: January 13, 2011Applicant: Medlmmune, LLCInventors: Subramaniam Krishnan, JoAnn Suzich, Peter Kiener, Genevieve Losonsky, Herren Wu, William Dall'Acqua, Bettina Richter
-
Publication number: 20100278838Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low Koff, thereby, inhibiting tumor cell growth and/or metastasis.Type: ApplicationFiled: April 7, 2010Publication date: November 4, 2010Applicant: MEDIMMUNE, LLCInventors: Michael S. Kinch, Kelly Carles-Kinch, Peter Kiener, Solomon Langermann
-
Publication number: 20100278813Abstract: The present invention relates to methods for broad spectrum prevention and treatment of viral respiratory infection. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with respiratory syncytial virus (RSV), parainfluenza virus (PIV), and/or human metapneumovirus (hMPV) infection, the methods comprising administering to a subject an effective amount of one or more anti-RSV-antigen antibodies or antigen-binding fragments thereof, one or more anti-hMPV-antigen antibodies or antigen-binding fragments thereof, and/or one or more anti-PIV-antigen antibodies or antigen-binding fragments thereof. In certain embodiments, a certain serum titer of the anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and/or anti-hMPV-antigen antibodies or antigen-binding fragments thereof is achieved in said subject.Type: ApplicationFiled: December 11, 2007Publication date: November 4, 2010Applicants: MedImmune, Inc., Vironovative B.V.Inventors: James F. Young, Peter Kiener, Albertus Dominicus Erasmus Osterhaus, Ronaldus Adrianus Maria Fouchier
-
Publication number: 20100261172Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.Type: ApplicationFiled: May 5, 2008Publication date: October 14, 2010Applicant: MEDIMMUNE, LLCInventors: Yihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener
-
Publication number: 20100143372Abstract: The present invention encompasses type-1 IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.Type: ApplicationFiled: December 6, 2007Publication date: June 10, 2010Applicant: MEDIMMUNE, LLCInventors: Yihong Yao, Bahija Jallal, Ricardo Cibotti, Anthony Coyle, Peter Kiener
-
Publication number: 20100093611Abstract: Methods of treating, ameliorating, preventing, or reducing the risk of developing an auto-immune disease and/or an inflammatory condition, such as systemic lupus erythematosus, in a patient, such as a human being, using a therapeutically effective amount of an agent(s) that inhibits the activity of one or more of histone deacetylase (HDAC), IKB kinase (IKK-2), nuclear factor kB (NF-kB), ubiquitin/proteasome and Janus kinase (JAK) are disclosed. Compounds useful in such methods are also presented.Type: ApplicationFiled: May 16, 2008Publication date: April 15, 2010Inventors: Stephen K. Horrigan, Qin Zong, Daniel Soppet, Juana Castaneda, Bo Chen, Ricardo Cibotti, Laurent P. Audoly, Anthony Coyle, Peter Kiener
-
Publication number: 20100061987Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: ApplicationFiled: August 3, 2009Publication date: March 11, 2010Applicant: MedImmune, LLCInventors: Herren Wu, Christian B. Allan, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle
-
Patent number: 7658921Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: June 13, 2007Date of Patent: February 9, 2010Assignee: MedImmune, LLCInventors: William Dall'Acqua, Herren Wu, Peter Kiener
-
Patent number: 7585504Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: GrantFiled: October 21, 2005Date of Patent: September 8, 2009Assignee: MedImmune, LLCInventors: Herren Wu, Christian B. Allan, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle
-
Publication number: 20090169546Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: ApplicationFiled: November 27, 2006Publication date: July 2, 2009Applicants: MEDIMMUNE, LLC, CRITICAL THERAPEUTICSInventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
-
Publication number: 20090162933Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of a non-neoplastic hyperproliferative cell or excessive cell accumulation disorders, particularly those involving hyperproliferation of epithelial or endothelial cells. In one embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and increase EphA2 cytoplasmic tail phosphorylation and/or increase EphA2 autophosphorylation, in cells which EphA2 has been agonized. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and reduce EphA2 activity (other than autophosphorylation). In another embodiment, the methods of the invention comprise administration of an effective amount of one or more EphA2 agonistic agents that bind to EphA2 and decrease a pathology-causing cell phenotype (e.g.Type: ApplicationFiled: July 22, 2008Publication date: June 25, 2009Inventors: Peter A. Kiener, Michael S. Kinch, Solomon Langermann, Jennifer L. Reed
-
Publication number: 20090148459Abstract: The present invention relates to methods and compositions designed for the treatment, management or prevention of cancer. The methods of the invention comprise the administration of an effective amount of one or more antagonists of Integrin ?V?3 alone or in combination with the administration of an effective amount of one or more other agents useful for cancer therapy. The invention also provides pharmaceutical compositions comprising one or more antagonists of Integrin ?V?3 and/or one or more other agents useful for cancer therapy. In particular, the invention is directed to methods of treatment and prevention of cancer by the administration of a therapeutically or prophylactically effective amount of one or more antagonists of Integrin ?V?3 alone or in combination with standard and experimental therapies for treatment or prevention of cancer. Also included are methods for screening for epitope-specific Integrin ?V?3 antagonists which can be used according to the methods of the invention.Type: ApplicationFiled: January 9, 2008Publication date: June 11, 2009Inventors: Richard Woessner, Peter Kiener, Melissa Dormitzer, William Walsh, Jon Heinrichs
-
Publication number: 20090130111Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.Type: ApplicationFiled: September 28, 2006Publication date: May 21, 2009Applicant: MEDIMMUNE, INC.Inventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Publication number: 20080311122Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, lupus, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.Type: ApplicationFiled: November 27, 2006Publication date: December 18, 2008Applicant: Medimmune, LLCInventors: Herren Wu, Ling-Ling An, Peter Kiener, Anthony Coyle, Jane Tian, Changsou Gao
-
Publication number: 20080305120Abstract: The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specially, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation.Type: ApplicationFiled: June 16, 2005Publication date: December 11, 2008Applicants: MEDIMMUNE, INC., THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCHInventors: Davorka Messmer, Kevin Tracey, Peter Kiener, Scott Alban
-
Publication number: 20080181887Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: ApplicationFiled: June 13, 2007Publication date: July 31, 2008Applicant: MEDIMMUNE, INC.Inventors: William Dall-Acqua, Herren Wu, Peter Kiener
-
Publication number: 20080138336Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.Type: ApplicationFiled: September 7, 2007Publication date: June 12, 2008Applicant: Medlmmune, Inc.Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
-
Publication number: 20080044413Abstract: The present invention relates to bispecific single chain antibodies comprising a first binding domain that immunospecifically binds to the T-cell antigen CD3 and a second binding domain that immunospecifically binds to the EphA2 receptor. Such bispecific single chain antibodies are encompassed by the term “EphA2-BiTEs.” The present invention further relates to methods and compositions designed for the treatment, prevention and/or management of disorders associated with aberrant expression and/or activity of EphA2. Such disorders include, but are not limited to, cancer, non-cancer hyperproliferative cell disorders, and infections. The invention further relates to vectors comprising polynucleotides encoding the EphA2-BiTEs of the invention, host cells transformed therewith, and their use in the production of said EphA2-BiTEs.Type: ApplicationFiled: December 21, 2006Publication date: February 21, 2008Inventors: Scott Hammond, Peter Kiener, Elizabeth Bruckheimer, Michael Kinch, Shannon Roff, Ralf Lutterbuese, Petra Lutterbuese, Bernd Schlereth, Patrick Baeuerle, Peter Kufer
-
Publication number: 20070166314Abstract: The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low Koff, thereby, inhibiting tumor cell growth and/or metastasis.Type: ApplicationFiled: March 12, 2007Publication date: July 19, 2007Inventors: Michael Kinch, Kelly Carles-Kinch, Peter Kiener, Solomon Langermann